Literature DB >> 19357740

Fluconazole resistant opportunistic oro-pharyngeal Candida and non-Candida yeast-like isolates from HIV infected patients attending ARV clinics in Lagos, Nigeria.

C A Enwuru1, A Ogunledun, N Idika, N V Enwuru, F Ogbonna, M Aniedobe, A Adeiga.   

Abstract

BACKGROUND: Oro-Pharyngeal Candidiasis (OPC) continues to be considered the most common opportunistic fungal disease in HIV/AIDS patients globally. Azole antifungal agent has become important in the treatment of mucosal candidiasis in HIV patients. Presently, antifungal drug resistance is fast becoming a major problem particularly with the immune depleted population.
OBJECTIVES: This study was designed to investigate the: existence of OPC, species distribution fluconazole susceptibility profile of yeast cells isolated from oral specimens of HIV/AIDS patients from Lagos Nigeria, between Oct. 2004 and June, 2005.
METHODOLOGY: The venous blood samples were screened for HIV antibodies using the Cappillus HIV I and II test kit (Trinity Biotech Plc UK), and Genie II HIV I and II EIA kit (Bio-Rad France). The positive results were subsequently confirmed at the laboratory attached to each of the clinics, using the Nigerian Federal Ministry of Health approved algorithm. The samples from 213 (108 females and 105 males) HIV positive patients were plated onto SD agar. The isolates were identified by morphotyping, microscopy and speciated using germ tube test and battery of biochemical sugar fermentation and assimilation tests. Fluconazole agar diffusion susceptibility testing was carried out on each isolates.
RESULTS: Seventy-four (34.7%) isolates were recovered including one person with double isolates. Only 70 (94.6%) of the isolates could be adequately speciated. Candida albicans 30 (40.5%) was the most frequently isolated species, the rest were non-albicans species, with the frequency of C. tropicalis > C. Krusei > C. glabrata and C. neoformans for species for species having up to 4 isolates. Four (30.8%) out of 13 isolates of C. tropicalis showed germ tube formation. While one C. albicans was germ-tube negative. Out of the 74 isolates tested for fluconazole sensitivity, 58 (78.4%) were sensitive, MIC d'' 8 microg/ml, 9 (12.1%) were susceptible Dose Dependent (SDD), MIC 16-32 microg/ml and 7 (9.5%) were resistant, MICs e'' 64 microg/ml. Among the C. albicans isolates, 26 (86.7%) were sensitive to fluconazole. The rank of susceptibility was C. albicans > C. tropicalis > C. Krusei for the most prevalent species.
CONCLUSION: We conclude that fluconazole resistant strains of oro-pharyngeal yeast-like cells exist in about 9.5% of HIV/AIDS patients with the above stated species distribution. We therefore, highlight the need for routine antifungal susceptibility testing on HIV patients with cases of initial or repeat episodes of OPC.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19357740      PMCID: PMC2583271     

Source DB:  PubMed          Journal:  Afr Health Sci        ISSN: 1680-6905            Impact factor:   0.927


  26 in total

1.  Phenotypic switching in Candida glabrata involves phase-specific regulation of the metallothionein gene MT-II and the newly discovered hemolysin gene HLP.

Authors:  S A Lachke; T Srikantha; L K Tsai; K Daniels; D R Soll
Journal:  Infect Immun       Date:  2000-02       Impact factor: 3.441

2.  Rapid methods for identification of yeasts.

Authors:  M Huppert; G Harper; S H Sun; V Delanerolle
Journal:  J Clin Microbiol       Date:  1975-07       Impact factor: 5.948

3.  Germ tube-positive Candida tropicalis.

Authors:  P M Tierno; M Milstoc
Journal:  Am J Clin Pathol       Date:  1977-08       Impact factor: 2.493

Review 4.  Update on clinical antifungal susceptibility testing for Candida species.

Authors:  R E Lewis; M E Klepser; M A Pfaller
Journal:  Pharmacotherapy       Date:  1998 May-Jun       Impact factor: 4.705

5.  The Candida albicans HYR1 gene, which is activated in response to hyphal development, belongs to a gene family encoding yeast cell wall proteins.

Authors:  D A Bailey; P J Feldmann; M Bovey; N A Gow; A J Brown
Journal:  J Bacteriol       Date:  1996-09       Impact factor: 3.490

Review 6.  Importance of Candida species other than Candida albicans as opportunistic pathogens.

Authors:  D C Coleman; M G Rinaldi; K A Haynes; J H Rex; R C Summerbell; E J Anaissie; A Li; D J Sullivan
Journal:  Med Mycol       Date:  1998       Impact factor: 4.076

7.  Epidemiology of oral candidiasis in HIV-infected patients: colonization, infection, treatment, and emergence of fluconazole resistance.

Authors:  J A Sangeorzan; S F Bradley; X He; L T Zarins; G L Ridenour; R N Tiballi; C A Kauffman
Journal:  Am J Med       Date:  1994-10       Impact factor: 4.965

8.  Risk factors for fluconazole-resistant candidiasis in human immunodeficiency virus-infected patients.

Authors:  J R Maenza; J C Keruly; R D Moore; R E Chaisson; W G Merz; J E Gallant
Journal:  J Infect Dis       Date:  1996-01       Impact factor: 5.226

9.  Comparative in vitro activity of antimycotic agents against pathogenic vaginal yeast isolates.

Authors:  M E Lynch; J D Sobel
Journal:  J Med Vet Mycol       Date:  1994

Review 10.  Emerging disease issues and fungal pathogens associated with HIV infection.

Authors:  N M Ampel
Journal:  Emerg Infect Dis       Date:  1996 Apr-Jun       Impact factor: 6.883

View more
  26 in total

1.  Using C. elegans for antimicrobial drug discovery.

Authors:  Athanasios Desalermos; Maged Muhammed; Justin Glavis-Bloom; Eleftherios Mylonakis
Journal:  Expert Opin Drug Discov       Date:  2011-06-01       Impact factor: 6.098

2.  Isolation and evaluation of Candida species and their association with CD4+ T cells counts in HIV patients with diarrhoea.

Authors:  Ayobami Awoyeni; Olarinde Olaniran; Babatunde Odetoyin; Rachel Hassan-Olajokun; Bolatito Olopade; David Afolayan; Oluwakayode Adekunle
Journal:  Afr Health Sci       Date:  2017-06       Impact factor: 0.927

3.  Fluconazole susceptibility and ERG11 gene expression in vaginal candida species isolated from Lagos Nigeria.

Authors:  Victoria K Pam; Juliet U Akpan; Oyinlola O Oduyebo; Francisca O Nwaokorie; Muinah A Fowora; Rita O Oladele; Folasade T Ogunsola; Stella I Smith
Journal:  Int J Mol Epidemiol Genet       Date:  2012-02-25

Review 4.  Pharmacokinetics and pharmacodynamics of antifungals in children and their clinical implications.

Authors:  Chris Stockmann; Jonathan E Constance; Jessica K Roberts; Jared Olson; Elizabeth H Doby; Krow Ampofo; Justin Stiers; Michael G Spigarelli; Catherine M T Sherwin
Journal:  Clin Pharmacokinet       Date:  2014-05       Impact factor: 6.447

5.  A study of antifungal drug sensitivity of Candida isolated from human immunodeficiency virus infected patients in Chennai, South India.

Authors:  Nadeem Jeddy; K Ranganathan; Uma Devi; Elizabeth Joshua
Journal:  J Oral Maxillofac Pathol       Date:  2011-05

6.  Oral candidiasis in HIV-uninfected pediatric population in areas with limited fungal diagnosis: A case study from a tertiary hospital, Tanzania.

Authors:  Martha F Mushi; Neema Loi; Stephen E Mshana
Journal:  Ther Adv Infect Dis       Date:  2021-05-20

7.  Association of oral candidal species with human immunodeficiency virus patients of West Godavari district, Andhra Pradesh - An in vitro study.

Authors:  R Mounika; Govindraj K Nalabolu; N Pallavi; Smita S Birajdar
Journal:  J Oral Maxillofac Pathol       Date:  2021-05-14

8.  Candida colonisation in asymptomatic HIV patients attending a tertiary hospital in Benin City, Nigeria.

Authors:  Newton O Esebelahie; Ifeoma B Enweani; Richard Omoregie
Journal:  Libyan J Med       Date:  2013-03-18       Impact factor: 1.743

9.  Profile of candidiasis in HIV infected patients.

Authors:  Khan P Anwar; A Malik; Khan H Subhan
Journal:  Iran J Microbiol       Date:  2012-12

10.  Frequent detection of 'azole' resistant Candida species among late presenting AIDS patients in northwest Ethiopia.

Authors:  Andargachew Mulu; Afework Kassu; Belay Anagaw; Beyene Moges; Aschalew Gelaw; Martha Alemayehu; Yeshambel Belyhun; Fantahun Biadglegne; Zewdu Hurissa; Feleke Moges; Emiko Isogai
Journal:  BMC Infect Dis       Date:  2013-02-12       Impact factor: 3.090

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.